Press Releases and Blog
Blog
ICYMI: New Report Underscores That Rebates Have No Correlation With High Drug Prices
In case you missed it, a new report from health policy researcher Alex Brill, founder and CEO of Matrix Global Advisors and former policy director
ICYMI: New Public Employee Policy Research Affirms PBMs Are Essential In Administering Pharmacy Benefits, Public Sector Employers Satisfied With Their Pharmacy Benefit Companies
In case you missed it, the National Institute for Public Employee Health Care Policy recently released a report, “How Public Sector Health Care Purchasers Are
ICYMI: Former Senator Pat Toomey Cautions Congress Against Proposals Targeting Pharmacy Benefit Companies
In case you missed it, WTOP’s Mitchell Miller spoke with former U.S. Senator Pat Toomey (R-PA) about the current health care debate in Congress in
ICYMI: Former Representative Altmire Joins Former U.S. Senator Pat Toomey In Cautioning Lawmakers Against Passing Proposals Targeting Pharmacy Benefits
In case you missed it, Jason Altmire, former Democratic three-term U.S. Representative from Pennsylvania and current adjunct professor at Texas Tech University, explains why so-called
ICYMI: “Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
So-called “delinking” policies continue to be discussed in Congress. Among several glaring problems — including a rejection of free market performance-based incentives that lower drug
ICYMI: Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
Press Releases
PCMA Statement On Legislation Introduced By Senate Finance Committee Members
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on legislation introduced by Finance Committee members: “While we’re currently reviewing
New PCMA Ad Campaign: Reject Big Pharma’s Agenda Designed To Keep Drug Prices High By Undermining Pharmacy Benefits
Congress Must Protect Savings and Choices for Patients and Employers by Rejecting Big Pharma’s Scheme to Eliminate the One Check on Their Pricing Power (Washington,
PCMA Statement on House Oversight Hearing
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement today ahead of the U.S. House Committee on
PCMA Statement on HELP Committee Vote on S. 1339
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on the legislative markup on S. 1339, the Pharmacy Benefit Manager
PCMA Announces Lucia Lebens as New Senior Vice President of Federal Affairs and Political Strategy
Named a 2022 Top Lobbyist by The Hill, Lebens Will Lead PCMA’s Federal Lobbying Team (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is
PCMA Launches Ad Campaign on Value of Pharmacy Benefit Companies and Solutions to Lower Prescription Drug Costs
Campaign Highlights How Pharmacy Benefit Companies Work Every Day to Secure Savings, Enable Better Health Outcomes, Support Access to Quality Rx Coverage and Promote Competition
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
ICYMI: Competitive Enterprise Institute Explains How Pharmacy Benefit Companies Lower Health Care Costs
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just
ICYMI: Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
ICYMI: New Survey Finds Overwhelming Majority of Employers Value a Wide Range of Pharmacy Benefit Company Contract Options
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you
Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.
House Hearing Underscores Misguided Proposals Targeting Pharmacy Benefit Companies Will Increase Drug Prices and Play Into Big Pharma’s Self-Serving Agenda
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy
ICYMI: Economic Experts Explain the Misunderstood Role of Pharmacy Benefit Managers
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re